North America Iron-Deficiency Anemia Therapy Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Mar 2020
  • North America
  • 350 Pages
  • No of Tables: 48
  • No of Figures: 30

Iron-Deficiency Anemia Therapy Market, By Therapy (Parenteral Iron Therapy and Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology and Others) Population (Adults, Pediatric and Geriatric), Country (U.S., Canada, Mexico), Market Trends and Forecast to 2027. 

North America Iron-Deficiency Anemia Therapy Market

Market Analysis and Insights: North America Iron-Deficiency Anemia Therapy Market

Iron-deficiency anemia therapy market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 17.6% in the forecast period of 2020 to 2027 and expected to reach USD 3,837.93 million by 2027. Growing prevalence of iron deficiency anemia and launch of the novel therapies is a driving factor for the market growth.

Innovation contributes to progress, the availability of biologicals, new drugs and lead products often mean new hope and better treatment options for patients and advances in health care for the population worldwide. Some products are new and innovative with a new approach which has never been used in clinical practice and bring potential benefits for the treatment of ongoing disease in the population worldwide. Various drugs and therapies are made with the help of advanced research and development, and rigorous testing, using items to verify their effectiveness.

Research and development, which continue to create new and innovative product, develop alternative treatments to reduce the side effects of constant drug to treat iron deficiency anemia and increase the potential for the treatment of deficiency in patients who do not respond to certain specific medications. Thus, it is driven by the growth of the world market of iron deficiency anemia.

This Iron-Deficiency Anemia Therapy Market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Iron-Deficiency Anemia Therapy Market

North America Iron-Deficiency Anemia therapy Market Scope and Market Size

North America iron-deficiency anemia therapy market is segmented on the basis of basis of therapy, therapy areas, and population. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of therapy, the market is segmented into oral iron therapy and parenteral iron therapy. In 2020, The oral therapy sector maintains a significant market share because oral treatment is mostly chosen for treatment of iron deficiency and parental iron treatment is generally given to patients who cannot absorb iron orally or if there is increase anemia even after adequate intake of oral iron supplements. Due to this reason the oral iron therapy segment dominates the iron deficiency anemia market.
  • On the basis of therapy areas, the market is segmented into inflammatory bowel disease, congestive heart failure (CHF), oncology, obstetrics and gynecology, renal and others. In 2020, the inflammatory bowel disease segment holds a major market share in the iron deficiency anemia market, as most of inflammatory bowel disease patients are suffering from persistent anemia. Anemia is a common symptom of inflammatory bowel disease which is caused by chronic blood loss and reduced absorption of iron due to tissue inflammation.
  • On the basis of population, the market is segmented into geriatric, adults and pediatric. In 2020, Adult segments hold a major share in iron deficiency anemia therapy market as pre-natal period and due to the decrease of body to menstrual fluid.

 Iron-Deficiency Anemia Therapy Market Country Level Analysis

Iron-deficiency anemia therapy market is analysed and market size information is provided by country, basis of therapy, therapy areas, and population as referenced above.

The countries covered in iron-deficiency anemia therapy market report are U.S., Canada and Mexico.

North America dominates the iron-deficiency anemia therapy market as in U.S, the iron-deficiency anemia therapy as quality health care system and the prevalence of anemia is an important indicator of health and remain a problem in the US health.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Incidences of Iron Deficiency Anemia

Iron-deficiency anemia therapy market also provides you with detailed market analysis for every country growth in industry with sales, components sales, impact of technological development in iron-deficiency anemia therapy and changes in regulatory scenarios with their support for the iron-deficiency anemia therapy market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Iron-Deficiency Anemia Therapy Market Share Analysis

Iron-deficiency anemia therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to North America iron-deficiency anemia therapy market.

The major players covered in the report are Vifor Pharma Ltd., AMAG Pharmaceuticals, FRESENIUS SE & CO. KGAA, Sanofi, Novartis AG, AbbVie Inc., Akebia Therapeutics, Inc., LUPIN, Orion Corporation, PHARMACOSMOS A/S, Teva Pharmaceutical Industries Ltd., Zydus Cadila, Rockwell Medical, GlaxoSmithKline plc., Alkem Labs, Hikma Pharmaceuticals PLC, Avion Pharmaceuticals, LLC, company among other domestic and North America players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product developments are also initiated by the companies worldwide which are also accelerating the growth of iron-deficiency anemia therapy market.

For instance,

  • In December 2018, Akebia Therapeutics, Inc. announces the successful completion of their merger with Keryx Biopharmaceuticals, Inc. This merger will help Akebia Therapeutics, Inc. to create a fully integrated kidney company that has candidates to set new standards of care for patients with kidney disease. This merger gave Akebia Therapeutics, Inc. Significant market opportunities with increased Auryxia growth and building launch momentum for the Phase 3 product candidates, vadadustat issued for approval by the US FDA.

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for iron-deficiency anemia therapy through expanded range of size.

Customization Available: North America Iron-Deficiency Anemia Therapy Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 PREVALENCE OF ANEMIA AMONG WOMEN OF REPRODUCTIVE AGE (% OF WOMEN AGES 15-49), (2013-2016)

TABLE 2 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, PIPELINE ANALYSIS

TABLE 3 NORTH AMERICA AND WHO REGIONAL MEAN BLOOD HAEMOGLOBIN CONCENTRATION AND PREVALENCE OF ANAEMIA BY POPULATION GROUP FOR 2011

TABLE 4 PREVALENCE OF ANEMIA IN CHILDREN OF AFRICA AND ASIA

TABLE 5 IRON DEFICIENCY ANEMIA THERAPEUTICS R&D ACTIVITIES

TABLE 6 CAUSES, PREVALENCE, AND CLINICAL CONSEQUENCES OF IRON DEFICIENCY IN INFLAMMATORY CONDITIONS

TABLE 7 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 9 NORTH AMERICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 10 NORTH AMERICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 11 NORTH AMERICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 12 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 13 NORTH AMERICA INFLAMMATORY BOWEL DISEASE IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 14 NORTH AMERICA RENAL IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 15 NORTH AMERICA RENAL IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 16 NORTH AMERICA OBSTETRICS AND GYNECOLOGY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 17 NORTH AMERICA CONGESTIVE HEART FAILURE (CHF) IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 18 NORTH AMERICA ONCOLOGY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 NORTH AMERICA OTHERS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 20 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2018-2027 (USD MILLION)

TABLE 21 NORTH AMERICA ADULTS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 22 NORTH AMERICA PEDIATRIC IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 23 NORTH AMERICA GERIATRIC IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 24 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 25 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 26 NORTH AMERICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 27 NORTH AMERICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 28 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 29 NORTH AMERICA RENAL IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 30 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2018-2027 (USD MILLION)

TABLE 31 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 32 U.S. ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 33 U.S. PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 34 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 35 U.S. RENAL IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 36 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2018-2027 (USD MILLION)

TABLE 37 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 38 CANADA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 39 CANADA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 40 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 41 CANADA RENAL IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 42 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2018-2027 (USD MILLION)

TABLE 43 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 44 MEXICO ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 45 MEXICO PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2018-2027 (USD MILLION)

TABLE 46 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 47 MEXICO RENAL IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREAS, 2018-2027 (USD MILLION)

TABLE 48 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2018-2027 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19